Optimizing treatment for patients with metastatic renal cell carcinoma in the central and Eastern European region

Bibliography

• Ferlay J, Shin HR, Bray F, Cancer Incidence and Mortality Worldwide: IARC CancerBase No. 10 [Internet]. GLOBOCAN 2008. Available from: http://globocan.iarc.fr [Last accessed 28 January 2011]
   Google Scholar
• Coleman MP, Gatta G, Verdecchia A, EUROCARE-3 summary: cancer survival in Europe at the end of the 20th century. Ann Oncol 2003;14(Suppl 5):v128-49
   PubMedGoogle Scholar
• Cancer Facts & Figures. MEPs Against Cancer, 2011. Available from: http://www.mepsagainstcancer.org/index.php?option=com_frontpage&Itemid=1 [Last accessed 16 August 2011]
   Google Scholar
• Escudier B, Kataja V. Renal cell carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2010;21(Suppl 5):v137-9
   PubMedGoogle Scholar
• Hsu CC, Chow WH, Boffetta P, Dietary risk factors for kidney cancer in eastern and central Europe. Am J Epidemiol 2007;166(1):62-70
   PubMed Web of Science ®Google Scholar
• Plesko I, Obsitnikova A, Cuninkova M, Increasing occurrence of urological cancers in Slovakia. Neoplasma 2004;51(4):248-54
   PubMedGoogle Scholar
• World Economic Outlook Database. International Monetary Fund
   Google Scholar
• Dusek L, Muzik J, Gelnarova E, Cancer incidence and mortality in the Czech Republic. Klin Onkol 2010;23(5):311-24
   PubMedGoogle Scholar
• Epidemiology of Malignant Tumors in the Czech Republic. Available from: http://www.svod.cz
   Google Scholar
• Onkoloski Institut Ljubljana. Available from: http://www.onko-i.si/dejavnosti/epidemiologija_in_register_raka/registri_raka/register_raka_rs/index.html
   Google Scholar
• International Agency for Research on Cancer. IARC Monographs on the Evaluation of Carcinogenic Risk to Humans. Lyon, France: International Agency for Research on Cancer; 2004
   Google Scholar
• Hunt JD, van der Hel OL, McMillan GP, Renal cell carcinoma in relation to cigarette smoking: meta-analysis of 24 studies. Int J Cancer 2005;114(1):101-8
   PubMed Web of Science ®Google Scholar
• WHO Global Infobase. World Health Organization, 2011. Available from: http://www.imf.org/external/pubs/ft/weo/2010/02/weodata/index.aspx [Last accessed 12 February 2011]
   Google Scholar
• Calle EE, Kaaks R. Overweight, obesity and cancer: epidemiological evidence and proposed mechanisms. Nat Rev Cancer 2004;4(8):579-91
   PubMed Web of Science ®Google Scholar
• Adams KF, Leitzmann MF, Albanes D, Body size and renal cell cancer incidence in a large US cohort study. Am J Epidemiol 2008;168(3):268-77
   PubMed Web of Science ®Google Scholar
• Oh SW, Yoon YS, Shin SA. Effects of excess weight on cancer incidences depending on cancer sites and histologic findings among men: Korea National Health Insurance Corporation Study. J Clin Oncol 2005;23(21):4742-54
   PubMedGoogle Scholar
• Pischon T, Lahmann PH, Boeing H, Body size and risk of renal cell carcinoma in the European Prospective Investigation into Cancer and Nutrition (EPIC). Int J Cancer 2006;118(3):728-38
   PubMed Web of Science ®Google Scholar
• Reeves GK, Pirie K, Beral V, Cancer incidence and mortality in relation to body mass index in the Million Women Study: cohort study. BMJ 2007;335(7630):1134
   PubMedGoogle Scholar
• Bergstrom A, Hsieh CC, Lindblad P, Obesity and renal cell cancer–a quantitative review. Br J Cancer 2001;85(7):984-90
   PubMed Web of Science ®Google Scholar
• Food, nutrition, physical activity, and the prevention of cancer: a global perspective. World Cancer Research Fund, American Institute for Cancer Research. American Institute for Cancer Research; Washington, DC: 2007
   Google Scholar
• Mahabir S, Leitzmann MF, Pietinen P, Physical activity and renal cell cancer risk in a cohort of male smokers. Int J Cancer 2004;108(4):600-5
   PubMedGoogle Scholar
• Moore SC, Chow WH, Schatzkin A, Physical activity during adulthood and adolescence in relation to renal cell cancer. Am J Epidemiol 2008;168(2):149-57
   PubMed Web of Science ®Google Scholar
• van Dijk BA, Schouten LJ, Kiemeney LA, Relation of height, body mass, energy intake, and physical activity to risk of renal cell carcinoma: results from the Netherlands Cohort Study. Am J Epidemiol 2004;160(12):1159-67
   PubMedGoogle Scholar
• Lee JE, Mannisto S, Spiegelman D, Intakes of fruit, vegetables, and carotenoids and renal cell cancer risk: a pooled analysis of 13 prospective studies. Cancer Epidemiol Biomarkers Prev 2009;18(6):1730-9
   PubMedGoogle Scholar
• Fyfe G, Fisher RI, Rosenberg SA, Results of treatment of 255 patients with metastatic renal cell carcinoma who received high-dose recombinant interleukin-2 therapy. J Clin Oncol 1995;13(3):688-96
   PubMed Web of Science ®Google Scholar
• Interferon-alpha and survival in metastatic renal carcinoma: early results of a randomised controlled trial. Medical Research Council Renal Cancer Collaborators. Lancet 1999;353:14-17
   PubMed Web of Science ®Google Scholar
• Pyrhonen S, Salminen E, Ruutu M, Prospective randomized trial of interferon alfa-2a plus vinblastine versus vinblastine alone in patients with advanced renal cell cancer. J Clin Oncol 1999;17(9):2859-67
   PubMed Web of Science ®Google Scholar
• Garcia JA, Rini BI. Recent progress in the management of advanced renal cell carcinoma. CA Cancer J Clin 2007;57(2):112-25
   PubMed Web of Science ®Google Scholar
• Motzer RJ, Bacik J, Murphy BA, Interferon-alfa as a comparative treatment for clinical trials of new therapies against advanced renal cell carcinoma. J Clin Oncol 2002;20(1):289-96
   PubMed Web of Science ®Google Scholar
• Mekhail TM, bou-Jawde RM, Boumerhi G, Validation and extension of the Memorial Sloan-Kettering prognostic factors model for survival in patients with previously untreated metastatic renal cell carcinoma. J Clin Oncol 2005;23(4):832-41
   PubMed Web of Science ®Google Scholar
• Negrier S, Escudier B, Gomez F, Prognostic factors of survival and rapid progression in 782 patients with metastatic renal carcinomas treated by cytokines: a report from the Groupe Francais d'Immunotherapie. Ann Oncol 2002;13(9):1460-8
   PubMed Web of Science ®Google Scholar
• Motzer RJ, Hutson TE, Tomczak P, Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med 2007;356(2):115-24
   PubMed Web of Science ®Google Scholar
• Motzer RJ, Hutson TE, Tomczak P, Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma. J Clin Oncol 2009;27(22):3584-90
   PubMed Web of Science ®Google Scholar
• Escudier B, Bellmunt J, Negrier S, Phase III trial of bevacizumab plus interferon alfa-2a in patients with metastatic renal cell carcinoma (AVOREN): final analysis of overall survival. J Clin Oncol 2010;28(13):2144-50
   PubMed Web of Science ®Google Scholar
• Escudier B, Pluzanska A, Koralewski P, Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial. Lancet 2007;370(9605):2103-11
   PubMed Web of Science ®Google Scholar
• Sternberg CN, Davis ID, Mardiak J, Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase III trial. J Clin Oncol 2010;28(6):1061-8
   PubMed Web of Science ®Google Scholar
• Hudes G, Carducci M, Tomczak P, Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. N Engl J Med 2007;356(22):2271-81
   PubMed Web of Science ®Google Scholar
• Escudier B, Eisen T, Stadler WM, Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med 2007;356(2):125-34
   PubMed Web of Science ®Google Scholar
• Escudier B, Szczylik C, Hutson TE, Randomized phase II trial of first-line treatment with sorafenib versus interferon Alfa-2a in patients with metastatic renal cell carcinoma. J Clin Oncol 2009;27(8):1280-9
   PubMed Web of Science ®Google Scholar
• Motzer RJ, Escudier B, Oudard S, Phase 3 trial of everolimus for metastatic renal cell carcinoma : final results and analysis of prognostic factors. Cancer 2010;116(18):4256-65
   PubMed Web of Science ®Google Scholar
• Motzer RJ, Escudier B, Oudard S, Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial. Lancet 2008;372(9637):449-56
   PubMed Web of Science ®Google Scholar
• Rini BI, Halabi S, Rosenberg JE, Phase III trial of bevacizumab plus interferon alfa versus interferon alfa monotherapy in patients with metastatic renal cell carcinoma: final results of CALGB 90206. J Clin Oncol 2010;28(13):2137-43
   PubMed Web of Science ®Google Scholar
• Di LG, Porta C, Bellmunt J, Toxicities of targeted therapy and their management in kidney cancer. Eur Urol 2011;59(4):526-40
   PubMedGoogle Scholar
• Rini BI, Escudier B, Tomczak P, Axitinib versus sorafenib as second-line therapy for metastatic renal cell carcinoma (mRCC): Results of phase III AXIS trial. J Clin Oncol 2011;29(Suppl):abstract 4503
   Google Scholar
• National Cancer Institute. National Cancer Institute 2011. Available from: http://www.cancer.gov/clinicaltrials
   Google Scholar
• Hellenthal NJ, Underwood W, Penetrante R, Prospective clinical trial of preoperative sunitinib in patients with renal cell carcinoma. J Urol 2010;184(3):859-64
   PubMed Web of Science ®Google Scholar
• Leppert JT, Pantuck AJ, Figlin RA, Belldegrun AS. The role of molecular markers in the staging of renal cell carcinoma. BJU Int 2007;99(5 Pt B):1208-11
   PubMedGoogle Scholar
• NCCN clinical practice guidelines in oncology: kidney cancer. Verson I.2012. National Comprehensive Cancer Network, Inc. 2011. Available from: http://www.nccn.org/professionals/physician_gls/pdf/kidney.pdf
   Google Scholar
• IMS Sutent Summary. Pfizer data on file
   Google Scholar
• World Health Statistics. Global Health Observatory. WHO, 2011. Available from: http://apps.who.int/ghodata/ [Last accessed 12 February 2011]
   Google Scholar
• Remak E, Charbonneau C, Negrier S, Economic evaluation of sunitinib malate for the first-line treatment of metastatic renal cell carcinoma. J Clin Oncol 2008;26(24):3995-4000
   PubMed Web of Science ®Google Scholar
• Laupacis A, Feeny D, Detsky AS, Tugwell PX. How attractive does a new technology have to be to warrant adoption and utilization? tentative guidelines for using clinical and economic evaluations. CMAJ 1992;146(4):473-81
   PubMed Web of Science ®Google Scholar